Tachykinins in endocrine tumors and the carcinoid syndrome

European Journal of Endocrinology

Volumn 159, Issue 3, 2008, Pages 275-282

  Cunningham, Janet L ^a   Janson, Eva T ^a   Agarwal, Smriti ^a   Grimelius, Lars ^a   Stridsberg, Mats ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; POLYCLONAL ANTIBODY; SEROTONIN; TACHYKININ; TACHYKININ ANTIBODY; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOID SYNDROME; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; ENDOCRINE TUMOR; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SYMPTOMATOLOGY; URINE LEVEL; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; BLOOD; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; RETROSPECTIVE STUDY; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ENDOCRINE GLAND NEOPLASMS; HUMANS; MALIGNANT CARCINOID SYNDROME; MOLECULAR SEQUENCE DATA; RETROSPECTIVE STUDIES; SEQUENCE HOMOLOGY; TACHYKININS; TUMOR MARKERS, BIOLOGICAL;

EID: 53249142651     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0196     Document Type: Article

References (51)

1. Sundler F, Alumets J & Håkanson R. 5-Hydroxytryptamine-containing enterochromaffin cells: storage site of substance P. Acta Physiologica Scandinavica 1977 452 121-123.
2. Wilander E, Portela-Gomes G, Grimelius L & Westermark P. Argentaffin and argyrophil reactions of human gastrointestinal carcinoids. Gastroenterology 1977 73 733-736.
3. Theodorsson-Norheim E, Norheim I, Öberg K, Brodin E, Lundberg JM, Tatemoto K & Lindgren PG. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients. Biochemical and Biophysical Research Communications 1985 131 77-83.
4. Norheim I, Wilander E, Öberg K, Theodorsson-Norheim E, Lundqvist ML, Lindgren P & Bergh J. Tachykinin production by carcinoid tumours in culture. European Journal of Cancer and Clinical Oncology 1987 23 689-695.
5. Chejfec G, Falkmer S, Askensten U, Grimelius L & Gould VE. Neuroendocrine tumors of the gastrointestinal tract. Pathology, Research and Practice 1988 183 143-154.
6. Bishop AE, Hamid OA, Adams C, Bretherton-Watt D, Jones PM, Denny P, Stamp GW, Hurt RL, Grimelius L, Harmar AJ, Valentino K, Cedermark B, Legon S, Ghatei MA, Bloom SR & Polak JM. Expression of tachykinins by ileal and lung carcinoid tumors assessed by combined in situ hybridization, immunocytochemistry, and radioimmunoassay. Cancer 1989 63 1129-1137.
7. Strodel WE, Vinik AI, Jaffe BM, Eckhauser FE & Thompson NW. Substance P in the localization of a carcinoid tumor. Journal of Surgical Oncology 1984 27 106-111.
8. Skrabanek P, Cannon D, Dempsey J, Kirrane J, Neligan M & Powell D. Substance P in medullary carcinoma of the thyroid. Experientia 1979 35 1259-1260.
9. Kakudo K & Vacca LL. Immunohistochemical study of substance P-like immunoreactivity in human thyroid and medullary carcinoma of the thyroid. Journal of Submicroscopic Cytology 1983 15 563-568.
10. Gamse R, Saria A, Bucsics A & Lembeck F. Substance P in tumors: pheochromocytoma and carcinoid. Peptides 1981 2 (Suppl 2) 275-280.
11. Nawa H, Hirose T, Takashima H, Inayama S & Nakanishi S. Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursor. Nature 1983 306 32-36.
12. Page NM. New challenges in the study of the mammalian tachykinins. Peptides 2005 26 1356-1368.
13. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S & Erspamer V. The tachykinin peptide family. Pharmacological Reviews 2002 54 285-322.
14. Improta G & Broccardo M. Tachykinins: role in human gastrointestinal tract physiology and pathology. Current Drug Targets 2006 7 1021-1029.
15. Beaujouan JC, Torrens Y, Saffroy M, Kernel ML & Glowinski J. A 25 year adventure in the field of tachykinins. Peptides 2004 25 339-357.
16. Norheim I, Theodorsson-Norheim E, Brodin E & Öberg K. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. Journal of Clinical Endocrinology and Metabolism 1986 63 605-612.
17. Norheim I, Theodorsson-Norheim E, Brodin E, Öberg K, Lundqvist G & Rosell S. Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumor tissues from patients with carcinoid tumors. Regulatory Peptides 1984 9 245-257.
18. Ahlman H, Dahlström A, Gronstad K, Tisell LE, Öberg K, Zinner MJ & Jaffe BM. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin. Annals of Surgery 1985 201 81-86.
19. Makridis C, Theodorsson E, Åkerström G, Öberg K & Knutson L. Increased intestinal non-substance P tachykinin concentrations in malignant midgut carcinoid disease. Journal of Gastroenterology and Hepatology 1999 14 500-507.
20. Valdovinos MA, Thomforde GM & Camilleri M. Effect of putative carcinoid mediators on gastric and small bowel transit in rats and the role of 5-HT receptors. Alimentary Pharmacology & Therapeutics 1993 7 61-66.
21. Grimelius L. A silver nitrate stain for aipha-2 cells in human pancreatic islets. Acta Societatis Medicorum Upsaliensis 1968 73 243-270.
22. Grimelius L & Wilander E. Silver stains in the study of endocrine cells of the gut and pancreas. Investigative & Cell Pathology 1980 3 3-12.
23. Solcia E, Klöppel G & Sobin LH. Histological Typing of Endocrine Tumours. WHO International Histological Classfflcation of Tumours. Berlin: Springer, 2000.
24. Stridsberg M, Öberg K, Li Q, Engström U & Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. Journal of Endocrinology 1995 144 49-59.
25. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K & Öberg K. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. Journal of Endocrinology 1993 139 329-337.
26. Wahlund KG & Edlen B. Simple and rapid determination of 5-hydroxyindole-3-acetic acid in urine by direct injection on a liquid chromatographic column. Clinica Chimica Acta 1981 110 71-76.
27. Moore BA, Kim D & Vanner S. Neural pathways regulating Brunner's gland secretion in guinea pig duodenum in vitro. American Journal of Physiology. Gastrointestinal and Liver Physiology 2000 279 G910-G917.
28. Lundqvist M & Wilander E. A study of the histopathogenesis of carcinoid tumors of the small intestine and appendix. Cancer 1987 60 201-206.
29. Moyana TN & Satkunam N. A comparative immunohistochemical study of jejunoileal and appendiceal carcinoids. Implications for histogenesis and pathogenesis. Cancer 1992 70 1081-1088.
30. Nilsson O, Dahlström A, Tisell LE, Lundberg JM, Theodorsson-Norheim E, Goldstein M & Ahlman H. Growth of human pheochromocytomas in the anterior eye chamber of the rat. A histochemical study on amine and peptide content of pheochromocytoma tumour cells. Regulatory Peptides 1986 15 129-141.
31. Norheim I, Öberg K, Theodorsson-Norheim E, Lindgren PG, Lundqvist G, Magnusson A, Wide L & Wilander E. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Annals of Surgery 1987 206 115-125.
32. Oates JA & Butler TC. Pharmacologic and endocrine aspects of carcinoid syndrome. Advances in Pharmacology 1967 5 109-128.
33. Oates JA, Pettinger WA & Doctor RB. Evidence for the release of bradykinin in carcinoid syndrome. Journal of Clinical Investigation 1966 45 173-178.
34. Sandler M, Karim SM & Williams ED. Prostaglandins in amine-peptide-secreting tumours. Lancet 1968 2 1053-1054.
35. Öberg K, Theodorsson-Norheim E & Norheim I. Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scandinavian Journal of Gastroenterology 1987 22 1041-1048.
36. Zuetenhorst JM, Korse CM, Bonfrer JM, Peter E, Lamers CB & Taal BG. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors. Clinical Chemistry 2004 50 1634-1639.
37. Lecci A, Capriati A & Maggi CA. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. British Journal of Pharmacology 2004 141 1249-1263.
38. Holzer P & Hotzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications. Current Opinion in Pharmacology 2001 1 583-590.
39. Cao W, Harnett KM & Pricolo VE. NK2 receptor-mediated spontaneous phasic contractions in normal and ulcerative colitis human sigmoid colon. Journal of Pharmacology and Experimental Therapeutics 2006 317 1349-1355.
40. Holzer P, Lippe IT, Heinernann A & Bartho L. Tachykinin NK1 and NK2 receptor-mediated control of peristaltic propulsion in the guinea-pig small intestine in vitro. Neuropharmacology 1998 37 131-138.
41. Kojima S, Ueda S, Ikeda M & Kamikawa Y. Calcitonin gene-related peptide facilitates serotonin release from guinea-pig colonic mucosa via myenteric neurons and tachykinin NK2/NK3 receptors. British Journal of Pharmacology 2004 141 385-390.
42. Robinson P, 0khuysen PC, Chappell CL, Weinstock JV, Lewis DE, Actor JK & White AC Jr. Substance P expression correlates with severity of diarrhea in cryptosporidiosis. Journal of Infectious Diseases 2003 188 290-296.
43. Bergström M, Theodorsson E, Norheim I & Oberg K. Immunoreactive tachykinins in 24-h collections of urine from patients with carcinoid tumours: characterization and correlation with plasma concentrations. Scandinavian Journal of Clinical and Laboratory Investigation 1995 55 679-689.
44. Saslow SB, O'Brien MD, Camilleri M, Von Der Ohe M, Homburger HA, Klee GG, Pitot HC & Rubin J. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. American Journal of Gastroenterology 1997 92 2250-2256.
45. Öberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist G & Wide L. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. Journal of Clinical Endocrinology and Metabolism 1989 68 796-800.
46. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, De Herder WW Goede A, Caplin M, Öberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P. Ahlman H & Wiedenann B. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004 80 394-424.
47. Öberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH & Valimaki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncologica 2004 43 617-625.
48. Turner GB, Johnston BT, Mccance DR, Mcginty A, Patterson CC, Watson PR & Ardill JE. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid turnours. Gut 2006 55 1586-1591.
49. Lordal M, Navalesi G, Theodorsson E, Maggi CA & Hellström PM. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. British Journal of Pharmacology 2001 134 215-223.
50. Newby DE, Sciberras DG, Ferro CJ, Gertz BJ, Sommerville D, Majumdar A, Lowry RC & Webb DJ. Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. British Journal of Clinical Pharmacology 1999 48 336-344.
51. Kordasti S, Sjövall H, Lundgren O & Svensson L. Serotonin and vasoactive intestinal peptide antagonists attenuate rotavirus diarrhoea. Gut 2004 53 952-957.